← ANALYST RATINGS · TIPRANKS
4D Molecular Therapeutics (FDMT): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $34.00, the highest $36.00, the lowest $33.00. The average is +180.1% from the last price of $12.14.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.00 → $12.50−3.8% | Hold | +3.0% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 → $12.50−3.8% | Hold | +3.0% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $14.00 → $13.00−7.1% | Hold | +7.1% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $13.50 → $12.50−7.4% | Hold | +3.0% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $13.50 → $12.50−7.4% | Hold | +3.0% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $14.00 → $13.00−7.1% | Hold | +7.1% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $28.00 | Buy | +130.6% | Reiterated | 13.10.26on TipRanks 04:50 | −4.9%next day −0.2% | ↗ |
| Name not given | — | $25.00 | Buy | +105.9% | Reiterated | 06.10.26on TipRanks Oct 7 06:11 | −3.3%next day +0.5% · 5 days −1.5% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | — | Hold | — | Reiterated | 28.09.26on TipRanks Sep 29 07:15 | +1.4%next day −0.3% · 5 days −12.5% | ↗ |
| Daniel Giraldo★★★★★★★★★★#1746 · hits 71% · avg +45.0% | Bank of America Securities | $29.00 → $33.00+13.8% | Buy | +171.8% | Reiterated | 28.09.26on TipRanks Sep 29 05:30 | +1.4%next day −0.3% · 5 days −12.5% | ↗ |
| Eric Schmidt FCA★★★★★★★★★★#358 · hits 51% · avg +84.1% | Cantor Fitzgerald | — | Buy | — | Upgrade | 21.09.26on TipRanks 10:40 | −1.4%next day +4.2% · 5 days −3.4% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $35.00 | Buy | +188.3% | Reiterated | 14.08.26on TipRanks 08:35 | +4.8%next day +19.8% · 5 days +31.2% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $36.00 | Buy | +196.5% | Reiterated | 14.08.26on TipRanks 06:35 | +4.8%next day +19.8% · 5 days +31.2% | ↗ |
| Unknown Analyst | B. Riley Securities | $37.00 | Buy | +204.8% | Initiated | 31.07.26on TipRanks Aug 5 21:06 | +0.4%next day −2.3% · 5 days +2.1% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $33.00 | Buy | +171.8% | Reiterated | 20.07.26on TipRanks Jul 24 05:14 | +1.1%next day +1.7% · 5 days −6.0% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $23.00 | Buy | +89.5% | Reiterated | 20.07.26on TipRanks Jul 24 05:14 | +1.1%next day +1.7% · 5 days −6.0% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $26.00 | Buy | +114.2% | Reiterated | 08.05.26on TipRanks 15:50 | +1.3%next day +6.2% · 5 days −10.0% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $40.00 → $21.00−47.5% | Buy | +73.0% | Initiated | 30.03.26on TipRanks 09:10 | −7.8%next day +5.7% · 5 days +15.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering 4D Molecular Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $32.14 at a price of $14.31 (+124.6%); now: $31.25 at $12.14 (+157.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 5 | 8 | 5 | 5 | 2 |
| Buy | 0 | 0 | 0 | 1 | 3 | 3 |
| Hold | 1 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.05 (from $-1.10 to $-0.99). Last quarter: $-1.04.
Sales
Next quarter’s sales estimate — $4M (from $0M to $6M). Last quarter: $4M.
Best top-analyst consensus in the sector · Healthcare
About 4D Molecular Therapeutics
- CEO: David H. Kirn
- Employees: 196
- 5858 Horton Street, EmeryVille, CA, 94608, US
- www.4dmoleculartherapeutics.com
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Data from the stock’s TipRanks forecast page, read 85 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗